Your Saliva Could Reveal Colorectal Cancer Risk, New Study Finds
Swabbing the inside of your cheek or rinsing your mouth takes about 30 seconds. A study published in Cell Host & Microbe on August 20, 2026, found that those 30 seconds may contain enough biological information to detect signs of two of the world’s deadliest cancers - without a stool sample, a needle, or a camera.
The research, led by Jihyun F. Kim, a systems biologist at Yonsei University in Seoul, South Korea, shows that by analyzing the makeup of oral microbes, researchers may be able to detect signals associated with gastric and colorectal cancer. The tool at the center of this finding is a saliva cancer prediction index built on a surprisingly direct concept: measuring how much of what lives in your mouth has also taken up residence in your gut.
The diagnostic classifiers the team built from oral samples outperformed standard fecal occult blood testing, and the signal remained effective using oral samples alone - pointing to a potentially noninvasive alternative to conventional stool-based cancer screening.
Colorectal cancer is the second leading cause of cancer-related mortality worldwide. Both colorectal and gastric cancers are among the most prevalent digestive tumors, characterized by high morbidity and mortality rates, and oral and intestinal microbiota appear to influence both diseases’ development.
Both cancers are highly survivable when caught early. The obstacle is getting people screened. Access to care, limited patient awareness, and anxiety about testing all reduce participation. A colonoscopy, while highly effective, requires bowel preparation, sedation, and recovery time. It remains the gold standard for colorectal cancer screening, but it carries risks of bowel perforation and bleeding that make some patients and clinicians reluctant. Even the less invasive stool-based alternatives carry limitations that this new research directly addresses.
The fecal occult blood test, often abbreviated as FOBT, is one of the most widely used first-line screening tools for colorectal cancer. It works by detecting traces of blood in a stool sample, which can signal that a polyp or tumor is bleeding internally. The logic is sound, but the execution is imperfect.
These tests have high rates of both false positives and false negatives. Blood in the stool can come from hemorrhoids, dietary sources, or other benign conditions unrelated to cancer. Not all cancerous or precancerous polyps bleed consistently, which means the test can return a clean result even when something is wrong.
A mouth rinse would bypass these limitations entirely - no stool collection, no needles, no bowel preparation.
How the Yonsei University Study Was Designed
The researchers used 16S ribosomal RNA sequencing to analyze paired oral and fecal samples from 507 participants: 77 people with stomach cancer, 86 with colorectal cancer, 215 with metabolic disorders, and 129 healthy controls. The metabolic disorder group included people with conditions such as hypertension, type 2 diabetes, and metabolic syndrome - a deliberate design choice that allowed the team to test whether the signal was specific to cancer or appeared across a range of diseases.
16S rRNA sequencing is a culture-free method used to identify and compare bacterial diversity from complex microbiomes, meaning researchers can characterize the full bacterial community of a sample without needing to grow individual species in a lab.
From these matched samples, the team created a mouth-to-feces (MF) index, which measures the extent to which identical microbial sequence variants appear in both the mouth and feces of the same person.
The Biological Logic Behind the Index
Researchers have increasingly found connections between the microbes living in the mouth and those found farther down the gastrointestinal tract. Some oral bacteria have also been linked to colorectal tumors, raising questions about whether disease may affect how easily these microbes travel to and establish themselves in the gut.
“Many species of microbes associated with the mouth are also present in the gut and may flourish there,” says lead author Jihyun F. Kim. “These observations made us wonder whether oral microbes reach and persist in the gastrointestinal tract differently in people with cancer.”
The Yonsei team took that question a step further. Rather than simply looking for particular oral bacteria in the gut, they measured the overall degree of microbial overlap between each person’s mouth and fecal samples. The resulting MF index gave the researchers a single number they could compare across people with stomach cancer, colorectal cancer, metabolic disorders, and healthy controls.
What the MF Index Revealed
The MF index was significantly elevated in people with gastrointestinal cancers compared to healthy controls. That elevation was not found in the metabolic disorder group, even though conditions like type 2 diabetes and hypertension are also associated with gut microbiome disruption. That specificity is what gives the index its potential diagnostic value.
After accounting for lifestyle factors including alcohol consumption, regular exercise, and BMI, the association remained robust for both gastric and colorectal cancers.
Cancer Patterns Differ by Disease Type
Patients with gastric cancer exhibited alterations primarily in their oral microbiota, whereas those with colorectal cancer showed significant changes in their fecal microbiota. For colorectal cancer specifically, the fecal changes could theoretically be detected at either end of the sampling spectrum - from a stool collection or, as this study suggests, from an oral sample alone.
Sun Ha Jee, an epidemiologist and co-corresponding author at Yonsei University, described what the data showed: “The presence of oral-associated bacteria in the gut of patients with cancer was not entirely unexpected. What we had not fully anticipated was how the signal varied across disease groups, how much of it could be detected in oral samples alone, and how strongly it depended on the way microbial features were represented.”
The Case for an Oral Rinse Screening Test
An oral-rinse test would be easy to collect and generally less burdensome than a stool test. It could help identify people who should be prioritized for established diagnostic procedures such as upper endoscopy or colonoscopy, functioning as a triage step rather than a replacement for confirmatory testing.
The broader push toward noninvasive options already has institutional momentum. The American Cancer Society has expanded its colorectal cancer screening recommendations to include additional stool-based and blood-based test options, reflecting the goal of lowering barriers to participation. An oral test would represent a further step in that direction, potentially reaching people who avoid even stool-based collection kits.
What Remains Unknown - and What Comes Next
The most pressing scientific question the study does not answer is the direction of causality. Do oral bacteria migrating into a compromised gut actively contribute to cancer development? Or does the tumor environment itself - the inflammation, altered pH, disrupted immune signaling - make it easier for oral bacteria to survive and proliferate there? The researchers acknowledge this openly, and future work will attempt to resolve it.
The study received financial support from the National Research Foundation of Korea and the Yonsei Signature Research Cluster Program. Beyond gastric and colorectal cancers, the team notes that this analytical framework could be expanded to a wider range of diseases, and may ultimately contribute to personalized risk prediction by integrating genetic, lifestyle, and clinical information.
The single clearest constraint on timeline is prospective validation. Prospective clinical studies are needed before the MF index could be used in clinical practice. The current data come from people who already had a confirmed cancer diagnosis, meaning the test was assessed retrospectively. Before it can function as a true screening tool, it needs to demonstrate that it can identify cancer in people who do not yet know they have it.
What This Means for You
Saliva-based cancer prediction is not yet available as a clinical offering - it remains a research finding. Colonoscopy and stool-based tests, despite their inconveniences and imperfections, are the options that save lives now. The American Cancer Society currently recommends colorectal cancer screening beginning at age 45 for average-risk adults, with test selection guided by patient preference and provider guidance. If you have not been screened and are 45 or older, the choice of test matters far less than making a choice at all.
An oral rinse that flags cancer risk with greater accuracy than a stool test, requires no preparation, and carries no procedural risk would remove substantial barriers to early detection. The biology supporting the concept is compelling. The clinical validation still has to catch up.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: These Foods Could Be Fueling the Surge in Early-Onset Colorectal Cancer Among Women
